CBL0137 | B2036

CBL0137 is a metabolically stable curaxin that activates p53 (EC₅₀ = 0.37 μM) and inhibits NF-κB (EC₅₀ = 0.47 μM). It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death. CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates efficacy of gemcitabine (Cat. No.1759 in preclinical models of pancreatic cancer.

CBL0137 is a metabolically stable curaxin that activates p53 (EC₅₀ = 0.37 μM) and inhibits NF-κB (EC₅₀ = 0.47 μM). It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death.

B2036 | CBL0137 DataSheet

Alternate Name/Synonyms: 1,1'-[9-[2-[(1-methylethyl)amino]ethyl]-9H-carbazole-3,6-diyl]-bis-ethanone; Curaxin 137

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 1197996-80-7

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₁H₂₄N₂O₂

Molecular Weight: 336.4

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (~5 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: Facilitates chromatin transcription (FACT) Inhibitor

MDL Number: N/A

PubChem CID: 44519124

SMILES: CC(C)NCCN1C2=C(C=C(C=C2)C(=O)C)C3=C1C=CC(=C3)C(=O)C

InChi: InChI=1S/C21H24N2O2/c1-13(2)22-9-10-23-20-7-5-16(14(3)24)11-18(20)19-12-17(15(4)25)6-8-21(19)23/h5-8,11-13,22H,9-10H2,1-4H3

InChi Key: JKCSODVERGVDLT-UHFFFAOYSA-N